Oxford, UK, 21 January 2021 – Argonaut Therapeutics, a leading developer of novel cancer agents, announced the appointment of Dr Chan Hee Park to its Board of Directors, representing key investor, JW Pharmaceutical Corporation. Dr Park is the Chief Technological Officer and Senior Vice President of JW Pharmaceutical Corporation. He has more than 25 years of R&D experience and he holds a Ph.D. in Medicinal and Pharmaceutical Chemistry from Seoul National University.
Professor Nick La Thangue, Founder and Chief Scientific Officer of Argonaut Therapeutics, and Professor of Cancer Biology in the Department of Oncology at Oxford University, commented:
“We are extremely pleased to welcome Dr Park to the Board. His expertise and continued support in Argonaut Therapeutics’ work in the development of drugs targeting arginine methylation will find clinical utility in diverse indications. Argonaut Therapeutics has an extensive collection of proprietary assets and the appointment of Dr Park will support us in moving swiftly towards the clinic.”
About Argonaut Therapeutics
Argonaut Therapeutics is a biopharmaceutical company developing new epigenetic therapies for treating cancer. Its lead programme is focussed on protein arginine methyltransferase 5 (PRMT5) which plays a key role in attaining the malignant phenotype in many different cancers. Argonaut’s deep scientific understanding of cancer-relevant pathways affected by arginine methylation enables a precision medicine approach to treating patients with responsive disease.
Argonaut Therapeutics is a spin-out of Oxford University and maintains a close relationship with the Division of Medical Sciences.